Apogee (APGE) raises $323M, updates APG777 atopic dermatitis and asthma trials

Apogee Therapeutics, Inc.

Offering of 6.95M shares at $41 plus pre-funded warrants and full underwriter option exercise, net proceeds ~$323.3M.
APG777 APEX atopic dermatitis trial enrollment increased to 320 patients; Part B enrollment expected by year-end 2025.
Topline maintenance data from APEX Part A expected Q1 2026; 16-week induction data from Part B in Q2 2026.
Phase 1b asthma topline data for APG777 expected in Q1 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.